prostate cancer
-
Bayer Unveils Promising Data on Investigational ²²⁵Ac-PSMA-Trillium for Advanced Metastatic Prostate Cancer
Bayer’s investigational therapy, ²²⁵Ac-PSMA-Trillium, shows promise for advanced prostate cancer. This targeted radionuclide therapy uses alpha-emitting ²²⁵Ac and a PSMA-targeting ligand to attack cancer cells. Clinical trial results are being reviewed for efficacy, safety, and commercial viability. The therapy could position Bayer as a leader in radiopharmaceuticals, though manufacturing and cost challenges remain. It represents a significant advancement beyond standard treatments, offering hope for overcoming resistance and improving patient outcomes.
-
VIR-5500: Promising Phase 1 Update for Metastatic Prostate Cancer Patients
Vir Biotechnology’s VIR-5500, a novel T-cell engager for advanced prostate cancer, showed promising safety and anti-tumor activity in Phase 1 trials. The therapy demonstrated significant PSA declines and objective responses in heavily pre-treated patients, with manageable side effects. This dual-targeting approach, utilizing PRO-XTEN® masking, aims for a differentiated therapeutic index, potentially offering a new option for patients with limited treatment choices.
-
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
Telix Pharmaceuticals reports significant progress in its precision medicine portfolio, especially in oncology. Key advancements include positive Phase 3 data for TLX591-CDx (Illuccix®) in China for prostate cancer imaging, meeting its primary endpoint and paving the way for a Chinese NDA submission. The company is also nearing NDA resubmission for TLX101-CDx (Pixclara®) in the U.S. and has aligned with the FDA on CMC deficiencies for TLX250-CDx (Zircaix®) BLA. These developments highlight Telix’s strategic focus on radiopharmaceutical innovation and market expansion.
-
CMS Awards Gozellix Transitional Pass-Through Status
Telix’s Gozellix receives Transitional Pass-Through (TPT) status from CMS, enabling separate reimbursement under HOPPS and eliminating 20% patient coinsurance starting October 1, 2025. Gozellix offers longer shelf life, broader distribution, and flexible production, improving PSMA-PET imaging accessibility for prostate cancer. While it advances diagnostics, potential risks include image misinterpretation, radiation exposure, and variable performance based on PSA levels. TPT status may significantly boost Telix’s market position.
-
Party With a Purpose: Republic Bank’s Fifth Annual Juneteenth Event Focuses on West Louisville Health
Republic Bank hosted its fifth annual Juneteenth event in Louisville, Kentucky, in partnership with Kentucky African Americans Against Cancer (KAAAC) and other organizations. They provided free health screenings and educational resources, particularly for West Louisville residents, focusing on prostate and oral health. This initiative builds on their commitment to community engagement and supporting local businesses.
